In line with these data, mutations and loss of CD58 expression are frequently observed in human leukemia and lymphomas, serving as adverse prognostic factors.28,30,34–38 Notably, CD58 deficiency in large B cell lymphomas hampers their response to chimeric antigen receptor-T (CAR-T) cell therapy.16,38 Moreover, melanoma that has developed resistance to ICB treatment exhibits significantly reduced CD58 expression compared to treatment-naive tumors.17 This evidence concerns the gene CD58 and lymphoma.